A
Aclaris Therapeutics, Inc.
ACRS · NASDAQ · Healthcare · 807M
Price · close
$6.41
+1.26% · last session
Graham & Buffett's criteria
published figures · last financial year
Price / earningsP/E
—
Price / net assetsP/B
7.6×
Enterprise value / EBITDAEV/EBITDA
-11.9×
Free cash flow yieldFCF yield
-6.0%
Return on equityROE
-63.0%
Operating margin
-975.9%
Net debt / EBITDAbalance-sheet strength
0.3×
Interest coverage
—
How we read it
an educational summary · not advice
Figures provided for information and education — they do not constitute personalized investment advice. Investing carries a risk of capital loss.